Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179525 · ClinicalTrials.gov registry record · Phase 1
Comparative Bioavailability of Risperidone.
A Phase 1 study of Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT05179525 is a Phase 1 study of Schizophrenia that has completed, run by Rovi Pharmaceuticals Laboratories. The registered enrollment target is 80 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05179525, a Phase 1 study of Schizophrenia, has completed, sponsored by Rovi Pharmaceuticals Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
Conditions Studied
Interventions
- DRUG Risperidone ISM® 100 mg
- DRUG Risperdal 4mg Tablet
Study Locations (4)
California
- Collaborative NeuroScience Research, LLC - Garden Grove
Maryland
- CBH Health, LLC - Gaithersburg
New Jersey
- Hassman Research Institute - Berlin
Texas
- Rajinder Shiwach - DeSoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05179525
The ClinicalTrials.gov registry entry for NCT05179525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The listed sponsor is Rovi Pharmaceuticals Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Risperidone ISM® 100 mg is the first listed.
NCT05179525 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05179525 about?
NCT05179525 is a clinical study titled "Comparative Bioavailability of Risperidone.". This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
What is the current status of trial NCT05179525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2021-03-09. Estimated completion is 2021-09-17.
What conditions does trial NCT05179525 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05179525?
The interventions under investigation include: Risperidone ISM® 100 mg (DRUG), Risperdal 4mg Tablet (DRUG).
Who is sponsoring clinical trial NCT05179525?
This trial is sponsored by Rovi Pharmaceuticals Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05179525 being conducted?
This trial has 4 study locations across California, Maryland, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.